Measles Exposure Risk in Immunosuppressed Patients

Critical Concerns

The Centers for Disease Control and Prevention recommends immediate immune globulin (IG) prophylaxis at a dose of 0.5 mL/kg body weight (maximum 15 mL) for immunocompromised patients on adalimumab, regardless of vaccination history, due to the risk of severe measles complications 1, 2, 3

The Centers for Disease Control and Prevention recommends administering intramuscular IG at 0.5 mL/kg body weight (maximum 15 mL) immediately if within 6 days of last contact with potentially infected individuals 1, 2, 4
IG can prevent or modify measles if given within 6 days of exposure, according to the Centers for Disease Control and Prevention 4
The higher dose (0.5 mL/kg vs. standard 0.25 mL/kg) is specifically indicated for immunocompromised hosts, as recommended by the Centers for Disease Control and Prevention 1, 2, 4

Measles-containing vaccine is explicitly not recommended for post-exposure prophylaxis in immunocompromised persons, as stated by the Centers for Disease Control and Prevention 4
The Centers for Disease Control and Prevention advises against waiting for symptoms to develop in contacts before giving IG, as the window for effective prophylaxis is narrow (6 days) 4
The Centers for Disease Control and Prevention recommends not assuming immunocompromised patients are protected by prior vaccination, as they may not be protected even if previously vaccinated 1, 2, 3
The Centers for Disease Control and Prevention recommends using the higher dose of 0.5 mL/kg IG for immunocompromised patients, rather than the standard dose of 0.25 mL/kg 1, 2, 4